OUR GROWTH STRATEGY
One of the secrets to our success is our repeatable and sustainable growth strategy, which complements our company's strengths and is backed up by a strong organizational structure to bridge the gap between aspirations and reality. At EVA Pharma, we base our regional growth strategy on four main imperatives, firstly Globally accredited Greenfield manufacturing facilities, development of branded generics, strong sustainable alliances, companies, innovative technologies, and product acquisitions.
WHY PARTNER WITH EVA PHARMA?
At EVA Pharma, we strongly believe in the catalytic effect of collaboration on successful, sustainable ventures. Our state-of-the-art manufacturing facilities are accredited by different regulatory entities including European authorities, sFDA, UAE, Bahrain, and GCC. Their impressive capabilities include the manufacturing of solids, parenteral, sterile eye drops, patches, liquids, and semisolids for a wide range of branded generics. This includes more than 165 products in the market and more than 500 molecules in the pipeline. Our strong manufacturing infrastructure is then armed with solid marketing, promotion, and a formidable distribution network that spans the region. EVA Pharma also has a notable collection of EU-CTD dossiers available.
